TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1303336
Drug: Pyrantel pamoate
Normalized name: Pyrantel Pamoate
DrugBank: Pyrantel (DB11156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrantel pamoate 10 mg/kg orally at a single dose
Study: 3512031
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (heparin fragment) 5000 anti-factor Xa units once daily
Study: 3512031
Drug: Conventional low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Conventional low-dose heparin 5000 units twice daily
Study: 16381629
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa 40,000 U weekly
Study: 11502918
Drug: Donepezil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (5 mg/day for 28 days, followed by 10 mg/day)
Study: 3392552
Drug: r-metHuIFN-Con1 at
Normalized name: R
Approvals — FDA: no, EMA: no, PMDA: no
Description: r-metHuIFN-Con1 at 30 mcg/m2/day
Study: 3392552
Drug: r-metHuIFN-Con1 at
Normalized name: R
Approvals — FDA: no, EMA: no, PMDA: no
Description: r-metHuIFN-Con1 at 45 mcg/m2/day
Study: 29939055
Drug: Cumulative habituation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumulative habituation across treatment
Study: 27289566
Drug: 30% decline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30% decline in circulating tumor cell (CTC) count after treatment
Study: 27289566
Drug: 30% CTC
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30% CTC decline after treatment from an initial count ≥5 cells/7.5 ml
Study: 22151005
Drug: High-dose (HD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose (HD) hydrocortisone regimen (30 mg daily) for 2 weeks
Study: 22151005
Drug: Low-dose (LD)
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose (LD) hydrocortisone regimen (17.5 mg daily) for 2 weeks
Study: 19152905
Drug: Endoscopic therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic therapies (including injection, thermocoagulation, clips)
Study: 18813410
Drug: Injection alone
Normalized name: U-Tri-Lone Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection alone
Study: 19152905
Drug: Injection followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection followed by thermal therapy
Study: 17573581
Drug: Tolvaptan (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolvaptan (doses not specified)
Study: 17573581
Drug: Change in
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Change in serum sodium (1 mmol/l increase)
Study: 8547730
Drug: Albuterol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (2 inhalations 4 times daily)
Study: 8547730
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 inhalations 4 times daily)
Study: 375732
Drug: Cefazolin (Ancef),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin (Ancef), administered intravenously in a high-dose, short perioperative regimen
Study: 21529775
Drug: Scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and root planing (SRP) plus clarithromycin (CLM) 500 mg b.i.d. for 3 days
Study: 19122034
Drug: FTY720 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: FTY720 1.25 mg/day
Study: 19122034
Drug: FTY720 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: FTY720 5.0 mg/day
Study: 19122034
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of FTY720 treatment
Study: 19122034
Drug: FTY720 (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: FTY720 (both doses) after 24 months
Study: 12370700
Drug: Daily pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily pain management diary with nurse coaching regarding the pain management program
Study: 12370700
Drug: Daily pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily pain management diary for data collection
Study: 7735515
Drug: Subcutaneous injections
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injections of a new, partially purified, characterized and standardized pollen extract of P. officinalis allergen (alum-absorbed depot preparation)
Study: 2525985
Drug: Etodolac (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etodolac (200 mg twice a day)
Study: 2525985
Drug: Piroxicam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam (20 mg once a day)
Study: 2525985
Drug: Diclofenac (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (50 mg three times a day)
Study: 11291357
Drug: Naproxen (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (500 mg twice a day)
Study: 31050763
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) + Care as Usual (CAU)
Study: 21327911
Drug: Talniflumate (740
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talniflumate (740 mg) with magnesium hydroxide (1 g)
Study: 21327911
Drug: Talniflumate (740
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talniflumate (740 mg) without magnesium hydroxide
Study: 11973101
Drug: Topical diclofenac
Normalized name: diclofenac Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diclofenac sodium 0.1%
Study: 2486579
Drug: Intravenous meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous meperidine 12.5 mg
Study: 2486579
Drug: Intravenous meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous meperidine 25 mg
Study: 29185604
Drug: Periodontal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periodontal therapy (PT)
Study: 23819226
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment (2HRZE/4HRE)
Study: 19852040
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg MMPD
Study: 19852040
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg MMPD
Study: 14740231
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of GSTM1 and GSTT1 null genotypes
Study: 9197352
Drug: Number of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Number of units of blood products administered during transplantation
Study: 7968324
Drug: Intrathecal meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal meperidine (0.2 mg/kg) with spinal tetracaine (12‐16 mg)
Study: 31705547
Drug: Insulin degludec/liraglutide
Normalized name: INSULIN DEGLUDEC/LIRAGLUTIDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin degludec/liraglutide (IDegLira)
Study: 31903724
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine 100 units/mL (IGlar U100)
Study: 30367884
Drug: Fluocinolone acetonide
Normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluocinolone acetonide (FA) insert (0.18 mg)
Study: 28963915
Drug: Subcutaneous trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous trastuzumab (Herceptin® SC) 600 mg fixed dose followed by intravenous trastuzumab (Herceptin®) 8 mg/kg loading, 6 mg/kg maintenance doses every 3 weeks.
Study: 28963915
Drug: Intravenous trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous trastuzumab (Herceptin®) 8 mg/kg loading, 6 mg/kg maintenance doses every 3 weeks followed by subcutaneous trastuzumab (Herceptin® SC) 600 mg fixed dose.
Study: 22704520
Drug: 23-valent pneumococcal
Normalized name: Streptococcus pneumoniae type 1 capsular polysaccharide antigen
DrugBank: Streptococcus pneumoniae type 1 capsular polysaccharide antigen (DB10319)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23-valent pneumococcal plain polysaccharide vaccine
Study: 20930212
Drug: Dose‐matched therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose‐matched therapeutic exercises (DMTE)
Study: 17141354
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine and aspart
Study: 17141354
Drug: NPH insulin
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH insulin and aspart
Study: 15099940
Drug: Selenium supplementation
Normalized name: Selenium supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium supplementation (200 microg, two capsules, four times daily)
Study: 3406455
Drug: Combined photon-low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined photon-low energy neutron treatment regimen (mixed beam)
Study: 3406455
Drug: Conventional photon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional photon and/or electron treatment
Study: 30890552
Drug: 15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg siltuximab
Study: 26298296
Drug: HBV vaccination
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBV vaccination at 20 μg (for children < 10 years) or 40 μg (for children > 10 years) at time 0, 1, and 6 months.
Study: 26298296
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received HBV vaccination at 10 μg (for children < 10 years) or 20 μg (for children > 10 years) at time 0, 1, and 6 months.
Study: 9783191
Drug: CMA therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMA therapy for 4 weeks before LH-RH analogue injection
Study: 9783191
Drug: CMA therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMA therapy for 2 weeks before LH-RH analogue injection
Study: 9783191
Drug: CMA therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMA therapy
Study: 30680617
Drug: 6-month program
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month program of weekly aerobic exercises associated with nutritional counseling (n = 41)
Study: 28614869
Drug: MA212 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: MA212 (40 mL daily)
Study: 21373969
Drug: Neoadjuvant temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Neoadjuvant temozolomide (TMZ) and 13‐cis retinoic acid (13‐cRA) treatment
Study: 17344769
Drug: Antihypertensive medication
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive medication adherence assessment via telephone questionnaire
Study: 9128029
Drug: Lidocaine 40
Normalized name: lidocaine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 40 mg (2 ml of lidocaine 2%) added to 180 mg of propofol (18 ml)
Study: 9128029
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (2 ml) added to 180 mg of propofol (18 ml)
Study: 9128029
Drug: Lidocaine 40
Normalized name: lidocaine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 40 mg premixed with 180 mg propofol
Study: 27040503
Drug: n‐3 PUFAs,
Approvals — FDA: no, EMA: no, PMDA: no
Description: n‐3 PUFAs, 1 g three times a day for 18 months
Study: 25378225
Drug: 5-grass pollen
Normalized name: grass pollen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-grass pollen sublingual tablet
Study: 15671806
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of metronidazole +/‐ 500 mg of ciprofloxacin
Study: 12353340
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg, increased to 20 mg after 8 weeks
Study: 12353340
Drug: Simvastatin 10
Normalized name: simvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 10 mg, increased to 20 mg after 8 weeks
Study: 10577635
Drug: Conventional antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional antihypertensive drugs (atenolol 50 mg, metoprolol 100 mg, pindolol 5 mg, or hydrochlorothiazide 25 mg plus amiloride 2.5 mg daily)
Study: 10577635
Drug: Newer antihypertensive
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Newer antihypertensive drugs (enalapril 10 mg or lisinopril 10 mg, or felodipine 2.5 mg or isradipine 2‐5 mg daily)
Study: 16138560
Drug: Conventional antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional antihypertensive drugs
Study: 10577635
Drug: Newer antihypertensive
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Newer antihypertensive drugs
Study: 8741162
Drug: Chlorpheniramine 4
Normalized name: chlorpheniramine 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine 4 mg
Study: 2987139
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal (50 g) given 5 min after dextropropoxyphene hydrochloride (130 mg)
Study: 2987139
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal (50 g) followed by 12.5 g at 6 h intervals
Study: 18346173
Drug: Metformin 850
Normalized name: metFORMIN 850 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 850 mg daily
Study: 31044492
Drug: Oral tetracycline
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tetracycline 250 mg bd and topical benzoyl peroxide 2.5%
Study: 15626549
Drug: Public Health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Public Health Dose (17.5 kcal/kg/week, 3 or 5 days/week)
Study: 15626549
Drug: Low Dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Dose (7.0 kcal/kg/week, 3 or 5 days/week)
Study: 12081121
Drug: L1 group
Normalized name: L1 protein, human papillomavirus type 11 vaccine
DrugBank: Human papillomavirus type 11 L1 capsid protein antigen (DB10300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L1 group (lower limbs in neutral position when analgesic level reached L1 dermatome)
Study: 12081121
Drug: T6 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: T6 group (lower limbs in neutral position when analgesic level reached T6 dermatome)
Study: 10208996
Drug: Corrected TIMI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corrected TIMI frame count (CTFC) measured at 90 minutes after thrombolytic administration.
Study: 8004854
Drug: Referral to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Referral to nursing, social work, physiotherapy, occupational therapy, or dietary services for potential discharge planning in Hospital A
Study: 8004854
Drug: Referral to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Referral to nursing, social work, physiotherapy, occupational therapy, or dietary services for potential discharge planning in Hospital B
Study: 2599668
Drug: Keto-analogues (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Keto-analogues (200 mg/kg/d) with low-protein diet (0.4 g/kg/d)
Study: 2599668
Drug: Keto-analogues (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Keto-analogues (200 mg/kg/d) with normal protein diet (1 g/kg/d)
Study: 21659488
Drug: Sprint exercise
Normalized name: norgestimate
DrugBank: Norgestimate (DB00957)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sprint exercise (30-s Wingate test) after glucose ingestion (n = 8, G)
Study: 18470779
Drug: Treatment program
Normalized name: ZO Skin Health Acne Prevention Plus Treatment Program KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment program based on evidence‐based treatments (EBTs) for disruptive behavior problems
Study: 16508257
Drug: Probiotic yogurt
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic yogurt (100 g/day for 2 weeks, then 200 g/day for 2 weeks)
Study: 16508257
Drug: Conventional yogurt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional yogurt (100 g/day for 2 weeks, then 200 g/day for 2 weeks)
Study: 10925331
Drug: Small-molecule IIb/IIIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small-molecule IIb/IIIa inhibitors (eptifibatide or tirofiban)
Study: 8226583
Drug: Fenfluramine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenfluramine (1.5 mg/kg per day)
Study: 8226583
Drug: Methylphenidate (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (0.4 mg/kg per day)
Study: 3536644
Drug: Ensure, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ensure, a defined formula dietary supplement
Study: 22699797
Drug: PASCET-PI (Primary
Approvals — FDA: no, EMA: no, PMDA: no
Description: PASCET-PI (Primary and Secondary Control Enhancement Therapy-Physical Illness)
Study: 16429182
Drug: Group 1
Normalized name: Chlamydophila psittaci biogroup 1 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 (no demineralizing agent)
Study: 16429182
Drug: Group 3
Normalized name: Chlamydophila psittaci biogroup 3 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 3 (17% EDTA solution, pH 7, for 3 min)
Study: 16429182
Drug: Group 4
Normalized name: Chlamydophila psittaci biogroup 4 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 4 (24% EDTA gel, pH 7, for 4 min)
Study: 12360101
Drug: Infliximab (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (5 mg/kg bodyweight)
Study: 10353855
Drug: Rimantadine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimantadine treatment
Study: 1936109
Drug: Total Parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total Parenteral Nutrition (TPN) during chemotherapy
Study: 1936109
Drug: Spontaneous oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spontaneous oral intake only (Control)
Study: 7287241
Drug: Amiloride (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride (5 mg) and Tienilic acid (250 mg)
Study: 7287241
Drug: Triamterene (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triamterene (100 mg) and Tienilic acid (250 mg)
Study: 7287241
Drug: Amiloride (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride (10 mg) and Tienilic acid (250 mg)
Study: 7287241
Drug: Triamterene (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triamterene (200 mg) and Tienilic acid (250 mg)
Study: 31261168
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of phenylephrine (P group)
Study: 31261168
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of norepinephrine (N group)
Study: 29028556
Drug: Intranasal methamphetamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal methamphetamine (0, 15, and 30mg)
Study: 22088800
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of 1 million autologous cardiac stem cells (CSCs) at a mean of 113 days after surgery.
Study: 23596142
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (5 mg)
Study: 7701971
Drug: Non-drug-dependent controls
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-drug-dependent controls
Study: 3109144
Drug: Tetracycline (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline (250 mg four times a day for 10 days)
Study: 3109144
Drug: Penicillin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penicillin (250 mg four times a day for 10 days)
Study: 3109144
Drug: Erythromycin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (250 mg four times a day for 10 days)
Study: 3109144
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous penicillin (20 million U a day for 10 days)
Study: 3109144
Drug: Intramuscular benzathine
Normalized name: Cephapirin Benzathine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular benzathine penicillin (7.2 million U)
Study: 3109144
Drug: Intravenous penicillin
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous penicillin G (20 million U a day for 10 days)
Study: 29705470
Drug: Routine prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine prescription (control group)
Study: 24440931
Drug: Cinitapride (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinitapride (1 mg)
Study: 3922052
Drug: Nitroglycerin ointment
Normalized name: Nitroglycerin Ointment
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin ointment (30 mg)
Study: 1648849
Drug: Sodium selenite
Normalized name: Sodium selenite
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Sodium selenite therapy
Study: 28379902
Drug: Cangrelor (Kengreal)
Normalized name: cangrelor Injection [Kengreal]
DrugBank: Cangrelor (DB06441)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cangrelor (Kengreal) administered as an intravenous infusion
Study: 28379902
Drug: Cangrelor (Kengreal)
Normalized name: cangrelor Injection [Kengreal]
DrugBank: Cangrelor (DB06441)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cangrelor (Kengreal) as bridging therapy
Study: 25138802
Drug: Third-wave cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third-wave cognitive therapy (n=22)
Study: 25138802
Drug: Mentalisation-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mentalisation-based treatment (n=22)
Study: 23173831
Drug: n-3 PUFA
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 PUFA (3g daily) for 5 weeks
Study: 15146330
Drug: L -5-Hydroxytryptophan
Normalized name: L-5-HTP
DrugBank: Oxitriptan (DB02959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L -5-Hydroxytryptophan (2 mg/kg per day) administered at bedtime for 20 consecutive days
Study: 2567178
Drug: Neostigmine (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine (various doses)
Study: 9526930
Drug: Droperidol 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 1.25 mg plus ondansetron 4 mg